Shares of Nurix Therapeutics surged 8.5% to $24.00 after the clinical-stage biotech reported third-quarter results that flipped its income statement from deep red to strikingly black. The headline numbers — $673.1 million in revenue, $549.8 million in net income — look transformative, but almost every dollar traces to a single, non-recurring event. For shareholders, the question is whether this cash infusion can buy enough time and clinical progress to justify a market cap now approaching $2.5 billion.

  • The Roche Check Was Big — and One-Time. Revenue of $673.1 million was driven primarily by a $653.2 million license payment from Nurix's Roche collaboration — a recognition of the upfront fee attached to a deal signed in June. That license revenue is non-recurring and relates specifically to a one-time license transfer. Strip it out, and quarterly revenue was roughly $20 million, mostly from smaller partnerships with Gilead, Pfizer, and Sanofi. Nurix posted earnings per share of $4.73, beating analyst estimates of $3.98 by about 19% , but next quarter's consensus already reverts to a -$0.39 loss — the reality of a company still years from product sales.

  • $1.1 Billion in Cash Buys Time, Not Certainty. Cash totaled $1.1 billion as of August 31, providing runway into the second half of 2029. That three-year cushion is critical because operating expenses hit $113.6 million in Q3 , and costs will rise as late-stage trials expand. Under the Roche deal, Nurix pays 40% of global development costs while Roche covers 60%, and the two split U.S. profits equally — a structure that protects Nurix's balance sheet but also caps its upside.

  • The Phase 3 Trial Is the Real Bet. Nurix enrolled the first patient in its Phase 3 trial comparing its lead drug — a protein degrader for blood cancers — against pirtobrutinib, the current standard treatment for relapsed chronic lymphocytic leukemia.

It is the first drug of its kind (a BTK degrader) to reach Phase 3 , a milestone that validates the science but also means the clinical bar is untested at a pivotal level. The trial plans to enroll roughly 620 patients , and results will take years.

  • Wall Street Sees Upside — With Caveats. Analysts currently assign an average price target of $34.64 , implying roughly 44% upside from today's price. Robert W. Baird raised its target to $36 with an "outperform" rating following the results. Yet of 15 analysts covering the stock, one still rates it a sell , reflecting the binary risk inherent in any pre-revenue biotech hinging on a single pivotal trial.